Management of Myopic Choroidal Neovascularization: Focus on Anti-VEGF Therapy

详细信息    查看全文

• 作者：Kelvin Yi Chong Teo ; Wei Yan Ng ; Shu Yen Lee ; Chui Ming Gemmy Cheung
• 刊名：Drugs
• 出版年：2016
• 出版时间：July 2016
• 年：2016
• 卷：76
• 期：11
• 页码：1119-1133
• 全文大小：1,540 KB
• 刊物主题：Pharmacotherapy; Pharmacology/Toxicology; Internal Medicine;
• 出版者：Springer International Publishing
• ISSN：1179-1950
• 卷排序：76

文摘

Myopic choroidal neovascularization (mCNV) is the second most common form of CNV after age-related macular degeneration (AMD). It is a sight-threatening complication of pathologic myopia (PM) and often affects patients in their working years causing significant impact on quality of life. Previous therapies such as photodynamic therapy with verteporfin have shown limited success. Due to the similarities in pathogenesis of mCNV and AMD CNV, anti-vascular endothelial growth factor therapy (anti-VEGF), which has so far been the mainstay of treatment for AMD CNV, has been shown to be effective in the treatment of mCNV and has become the first-line treatment of choice. This article aims to examine briefly the epidemiology and pathophysiology of mCNV, as well as review the evidence for efficacy, safety, and clinical use of anti-VEGF treatment for mCNV.